Stockholders approve increase in share reserve for 2006 Stock Incentive Plan to 17.5M shares

Protalix BioTherapeutics, Inc.

Seven directors elected; CEO Dror Bashan among those with over 22M for votes.
Advisory vote on executive compensation passed: 17.0M for, 9.88M against.
Stock plan amended: shares available increased from ~12.5M to 17,475,171.
Kesselman & Kesselman (PwC Israel) ratified as auditor for fiscal 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.